ADC Therapeutics targets $600M-$1B U.S. peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June
ADC Therapeutics SA · PHARMACEUTICAL PREPARATIONS · Now $3.40
-5.4% in 7d after detection
Post-detection moves
1h
—
1d
+2.2%
3d
+1.9%
7d
-5.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS